Castle | $1,000,000 | (Jun 27, 2025)
Handspring Health | $12,000,000 | (Jun 27, 2025)
DejaBlue | $8,000,000 | (Jun 27, 2025)
Certified by Founder
Lodge
Cedilla Therapeutics
start up
United States
- Cambridge, Massachusetts
- 25/10/2021
- Series B
- $25,000,000
For 60 years, sequence and structure has been the primary lens to understand protein function. It’s now time to look beyond and leverage the orchestration of protein function within cells.
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2.
We are a driven and patient-focused team.
- Industry Biotechnology Research
- Website https://www.cedillatx.com/
- LinkedIn https://www.linkedin.com/company/cedillatherapeutics/
Related People
Alexandra (Sandra) GlucksmannFounder
United States -
Cambridge, Massachusetts,
I love working within a team to help build great biotech companies.
Certify | $40,000,000 | (Jun 27, 2025)
Tacta Systems, Inc. | $7,000,000 | (Jun 27, 2025)
Antler Bio | $4,212,546 | (Jun 27, 2025)
Raphe mPhibr | $100,000,000 | (Jun 27, 2025)
DataBahn.ai | $17,000,000 | (Jun 27, 2025)
Klutch AI | $8,000,000 | (Jun 27, 2025)
Niural | $31,000,000 | (Jun 27, 2025)
Jarsy Inc | $5,000,000 | (Jun 27, 2025)
Spekter Games | $5,000,000 | (Jun 27, 2025)